What is Avasa?
Founded in 2018, Avasa is dedicated to advancing reconstructive microsurgery through the development of novel medical devices. The company is on the cusp of launching its flagship product, the Avasa Coupler. This device is engineered to standardize and streamline the intricate process of arterial reconnections, a critical step in many reconstructive procedures. Avasa's innovation aims to improve surgical outcomes and efficiency in a specialized field of medicine.
How much funding has Avasa raised?
Avasa has raised a total of $1.6M across 1 funding round:
Other Financing Round
$1.6M
Other Financing Round (2023): $1.6M with participation from Pacific Channel, The NZGCP, and Brisbane Angels
Key Investors in Avasa
Pacific Channel
Pacific Channel is a leading Asia-Pacific funds management firm specializing in deep-tech, venture capital, and alternative investments, particularly in health and environmental sectors. They support early-stage to Series A companies with innovative solutions.
The NZGCP
The NZGCP provides investment support for New Zealand innovators building world-class technology companies, offering seed funding and venture capital through initiatives like the Aspire NZ Seed Fund and Elevate NZ Venture Fund.
Brisbane Angels
Brisbane Angels is Australia's largest angel investing group, connecting experienced investors with high-growth, early-stage startups. They focus on companies with exceptional opportunities for high returns and sustainable advantages.
What's next for Avasa?
With the recent influx of capital and the impending launch of the Avasa Coupler, the company is poised for a significant growth phase. This funding is expected to support market entry, further product development, and the expansion of Avasa's operational capabilities. The strategic backing from prominent investors suggests a clear path towards scaling its impact within the medical device industry and potentially exploring new applications for its technology.
See full Avasa company page
